There's growing evidence to suggest that GLP-1 drugs, which include semaglutide, may be useful for treating alcohol use disorder.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Sure, who wouldn’t want to lose a few pounds? But what’s really driving Hollywood’s latest trend is the drug’s seemingly miraculous side benefits ...

Impact on brown adipose tissue: Berberine may lower weight by increasing brown adipose tissue, a type of fat tissue that ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...